Literature DB >> 28898584

In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance.

Hao Xu1, Socrates Vela1, Yi Shi1, Patrick Marroum1, Ping Gao1.   

Abstract

Ritonavir (RTV) is a weakly basic drug with a pH-dependent solubility. In vitro dissolution and supersatuation behaviors of three Norvir oral products including the tablet, powder, and solution were investigated by two biorelevant dissolution methods with pH alteration: a two-stage dissolution test and a biphasic dissolution-partition test. The two-stage dissolution test revealed a high degree of supersaturation of RTV from these products accompanied by the occurrence of liquid-liquid phase separation (LLPS) in biorelevant dissolution media. Higher, stable apparent RTV concentrations were observed in the FeSSIF-V2 as compared to those in the FaSSIF-V2, which suggested a food effect with higher exposure in the fed state. This is inconsistent with the evaluation in vivo. The biphasic test revealed significantly lower degrees of supersaturation of RTV in the aqueous media from these dosage forms as compared to results of the two-stage dissolution test. RTV concentrations in octanol at 6 h obtained from the tablet and powder with the use of the biorelevant media are consistent with corresponding in vivo AUC and Cmax under the fasting and moderate fat fed (MFF) states and predict the food effect. The underlying mechanisms responsible for the food effect are also proposed. Fractional partition profiles of RTV obtained in octanol from these three Norvir oral products are in agreement with the corresponding fractional absorption profiles in vivo under both the fasting and MFF states. This study reveals a complex interplay among the dissolution, precipitation, and partition processes from these formulations that dictate the oral exposure of RTV.

Entities:  

Keywords:  BCS; IVIVR; Wagner−Nelson method; absorption; biphasic; dissolution; food effect; in vitro models; partition; relative bioavailability; ritonavir

Mesh:

Substances:

Year:  2017        PMID: 28898584     DOI: 10.1021/acs.molpharmaceut.7b00552

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

1.  "Development of Fixed Dose Combination Products" Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.

Authors:  Bart Hens; Maura Corsetti; Marival Bermejo; Raimar Löbenberg; Pablo M González; Amitava Mitra; Divyakant Desai; Dakshina Murthy Chilukuri; Alexis Aceituno
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

2.  A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.

Authors:  Sumit Arora; Amita Pansari; Peter J Kilford; Masoud Jamei; David B Turner; Iain Gardner
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-04-29       Impact factor: 2.441

3.  In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.

Authors:  Yasuhiro Tsume; Sanjaykumar Patel; Nikoletta Fotaki; Christel Bergstrӧm; Gordon L Amidon; James G Brasseur; Deanna M Mudie; Duxin Sun; Marival Bermejo; Ping Gao; Wei Zhu; David C Sperry; Maria Vertzoni; Neil Parrott; Robert Lionberger; Atsushi Kambayashi; Andre Hermans; Xujin Lu; Gregory E Amidon
Journal:  AAPS J       Date:  2018-09-06       Impact factor: 4.009

4.  Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs.

Authors:  Deanna M Mudie; Aaron M Stewart; Jesus A Rosales; Nishant Biswas; Molly S Adam; Adam Smith; Christopher D Craig; Michael M Morgen; David T Vodak
Journal:  Pharmaceutics       Date:  2021-04-15       Impact factor: 6.321

5.  On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.

Authors:  Patrick J O'Dwyer; Karl J Box; Georgios Imanidis; Maria Vertzoni; Christos Reppas
Journal:  Eur J Pharm Sci       Date:  2021-10-07       Impact factor: 4.384

6.  On the Usefulness of Two Small-Scale In Vitro Setups in the Evaluation of Luminal Precipitation of Lipophilic Weak Bases in Early Formulation Development.

Authors:  Patrick J O'Dwyer; Georgios Imanidis; Karl J Box; Christos Reppas
Journal:  Pharmaceutics       Date:  2020-03-16       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.